Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Novel agent addresses role of oxidative stress in DME.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Boyer, David S.1
- Source:
Ophthalmology Times. 7/1/2018, Vol. 43 Issue 11, p37-39. 3p.
- Subject Terms:
- Additional Information
- Abstract:
The article discusses updates on the development of anti-integrin therapy (AIT) that address oxidative stress pathways in diabetic macular edema (DME). Topics mentioned include SciFluor Life Sciences' development of the topical AIT agent SF0166, the completion of the two phase IIb DME trials on Allegro Ophthalmics' integrin inhibitor risuteganib, and the results of studies including the reduction in leukocyte attachment by downregulation of integrin in ischemic, retinopathy of prematurity mice.
No Comments.